A critical appraisal of blood-based biomarkers for Alzheimer's disease
Biomarkers that predict the clinical onset of Alzheimer's disease (AD) enable the
identification of individuals in the early, preclinical stages of the disease. Detecting AD at this …
identification of individuals in the early, preclinical stages of the disease. Detecting AD at this …
The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022
DP Veitch, MW Weiner, M Miller, PS Aisen… - Alzheimer's & …, 2024 - Wiley Online Library
Abstract The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to improve
Alzheimer's disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging …
Alzheimer's disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging …
Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment
P Kivisäkk, BC Carlyle, T Sweeney… - Frontiers in …, 2023 - frontiersin.org
Background The last few years have seen major advances in blood biomarkers for
Alzheimer's Disease (AD) with the development of ultrasensitive immunoassays, promising …
Alzheimer's Disease (AD) with the development of ultrasensitive immunoassays, promising …
Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline …
Y Huang, Y Li, F Xie, Q Guo - CNS Neuroscience & …, 2022 - Wiley Online Library
Aims There is increasing evidence that plasma biomarkers are specific biomarkers for
Alzheimer's disease (AD) pathology, but their potential utility in Obj‐SCD (objectively …
Alzheimer's disease (AD) pathology, but their potential utility in Obj‐SCD (objectively …
Association of plasma phosphorylated tau with the response to neflamapimod treatment in patients with dementia with Lewy bodies
JJ Alam, P Maruff, SR Doctrow, HM Chu, J Conway… - Neurology, 2023 - AAN Enterprises
Background and Objectives In a proportion of patients, dementia with Lewy bodies (DLB) is
associated with Alzheimer disease (AD) copathology, which is linked to accelerated …
associated with Alzheimer disease (AD) copathology, which is linked to accelerated …
Predictive blood biomarkers and brain changes associated with age-related cognitive decline
TS Saunders, FE Pozzolo, A Heslegrave… - Brain …, 2023 - academic.oup.com
Growing evidence supports the use of plasma levels of tau phosphorylated at threonine 181,
amyloid-β, neurofilament light and glial fibrillary acidic protein as promising biomarkers for …
amyloid-β, neurofilament light and glial fibrillary acidic protein as promising biomarkers for …
Comorbidity‐driven multi‐modal subtype analysis in mild cognitive impairment of Alzheimer's disease
S Katabathula, PB Davis, R Xu - Alzheimer's & Dementia, 2023 - Wiley Online Library
Background Mild cognitive impairment (MCI) is a heterogeneous condition with high
individual variabilities in clinical outcomes driven by patient demographics, genetics, brain …
individual variabilities in clinical outcomes driven by patient demographics, genetics, brain …
Non-invasive biomarkers for early detection of Alzheimer's disease: a new-age perspective
NMA Chimthanawala, A Haria, S Sathaye - Molecular Neurobiology, 2024 - Springer
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that primarily affects
the elderly population. It gradually leads to memory loss, loss of thinking ability, and an …
the elderly population. It gradually leads to memory loss, loss of thinking ability, and an …
Plasma Markers of Alzheimer's Disease Pathology, Neuronal Injury, and Astrocytic Activation and MRI Load of Vascular Pathology and Neurodegeneration: The …
EL Twait, L Gerritsen, JEF Moonen… - Journal of the …, 2024 - Am Heart Assoc
Background Two of the main causes for dementia are Alzheimer's disease (AD) and
vascular pathology, with most patients showing mixed pathology. Plasma biomarkers for …
vascular pathology, with most patients showing mixed pathology. Plasma biomarkers for …
Electrochemical impedance-based biosensor for label-free determination of plasma P-tau181 levels for clinically accurate diagnosis of mild cognitive impairment and …
Plasma phosphorylated-tau threonine 181 (p-tau181) is a promising biomarker for predicting
Alzheimer's disease (AD) and mild cognitive impairment (MCI), which is the symptomatic pre …
Alzheimer's disease (AD) and mild cognitive impairment (MCI), which is the symptomatic pre …